SK Chemicals receives FDA approval for SID710SK Chemicals said Wednesday it has won approval from the U.S. Food and Drug Administration (FDA) to sell its patch-type Alzheimer’s drug in the United States.
SID710, the generic drug referencing Novartis AG’s Exelon Patch to treat dementia symptoms associated with Alzheimer’s disease, received the green light from the FDA.
The approval marked the first time a South Korean company has applied for FDA approval for an Alzheimer’s patch on its own and received it.
More in Industry
Eastar Jet's pilot union pushes for receivership of airline
ITC agrees to review its decision in Botox dispute
Hyundai Motor and union come to a wage freeze deal
Samsung Biologics signs supply deal with AstraZeneca
Tesla to increase battery cell purchases from suppliers including LG